Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines announced it will present data from its RAS(ON) inhibitor pipeline at the 2026 ESMO Gastrointestinal Cancers Congress in Munich. The program includes two oral presentations on Phase 1/2 trials evaluating zoldonrasib in combination regimens for metastatic pancreatic ductal adenocarcinoma.
Key figures
- Drug Name
- zoldonrasib and daraxonrasib
- Phase Of Trial
- Phase 1/2 and Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.